You are here

J Clin Invest DOI:10.1172/JCI66343

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.

Publication TypeJournal Article
Year of Publication2013
AuthorsSerra, V, Eichhorn, PJA, García-García, C, Ibrahim, YH, Prudkin, L, Sánchez, G, Rodríguez, O, Antón, P, Parra, J-L, Marlow, S, Scaltriti, M, Pérez-Garcia, J, Prat, A, Arribas, J, Hahn, WC, Kim, SYoung, Baselga, J
JournalJ Clin Invest
Volume123
Issue6
Pages2551-63
Date Published2013 Jun
ISSN1558-8238
KeywordsAminopyridines, Animals, Antineoplastic Agents, Apoptosis, Breast Neoplasms, Cell Survival, Drug Resistance, Neoplasm, Drug Synergism, Female, Gene Expression, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Heterocyclic Compounds, 3-Ring, Humans, Imidazoles, MCF-7 Cells, Mice, Mice, Nude, Molecular Targeted Therapy, Morpholines, Open Reading Frames, Phosphatidylinositol 3-Kinases, Quinolines, Ribosomal Protein S6 Kinases, 90-kDa, Signal Transduction, Transcriptome, Tumor Burden, Xenograft Model Antitumor Assays
Abstract

The PI3K signaling pathway regulates diverse cellular processes, including proliferation, survival, and metabolism, and is aberrantly activated in human cancer. As such, numerous compounds targeting the PI3K pathway are currently being clinically evaluated for the treatment of cancer, and several have shown some early indications of efficacy in breast cancer. However, resistance against these agents, both de novo and acquired, may ultimately limit the efficacy of these compounds. Here, we have taken a systematic functional approach to uncovering potential mechanisms of resistance to PI3K inhibitors and have identified several genes whose expression promotes survival under conditions of PI3K/mammalian target of rapamycin (PI3K/mTOR) blockade, including the ribosomal S6 kinases RPS6KA2 (RSK3) and RPS6KA6 (RSK4). We demonstrate that overexpression of RSK3 or RSK4 supports proliferation upon PI3K inhibition both in vitro and in vivo, in part through the attenuation of the apoptotic response and upregulation of protein translation. Notably, the addition of MEK- or RSK-specific inhibitors can overcome these resistance phenotypes, both in breast cancer cell lines and patient-derived xenograft models with elevated levels of RSK activity. These observations provide a strong rationale for the combined use of RSK and PI3K pathway inhibitors to elicit favorable responses in breast cancer patients with activated RSK.

URLhttp://dx.doi.org/10.1172/JCI66343
DOI10.1172/JCI66343
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/23635776?dopt=Abstract

Alternate JournalJ. Clin. Invest.
PubMed ID23635776
PubMed Central IDPMC3668839
Grant ListR01 CA130988 / CA / NCI NIH HHS / United States
U54CA112962 / CA / NCI NIH HHS / United States
CA148268 / CA / NCI NIH HHS / United States
U54 CA112962 / CA / NCI NIH HHS / United States
RC2 CA148268 / CA / NCI NIH HHS / United States